SERB Pharmaceuticals Acquires Idefirix® European and MENA Rights from Hansa Biopharma for €115 Million
SERB Pharmaceuticals has agreed to pay €115 million for exclusive development and commercialization rights to Idefirix® (imlifidase) across Europe and the Middle East and North Africa, acquiring the asset from Hansa Biopharma AB (Nasdaq…
By Lena Park·Jun 23, 2026·2 min read·markets
Source: NewsMeter
© 2026 NewsMeter
Markets · INTCJul 27, 2026
Intel Corporation's overvaluation question surfaces in Seeking Alpha analysis
1 min
Markets · AMZNJul 27, 2026
Amazon files for 5,105-satellite constellation, targeting direct-to-device mobile by 2028
2 min
Markets · NVDAJul 27, 2026
Nvidia invests in Safe Superintelligence with terms undisclosed
1 min